Alopecia areata: progress, but who pays?
- PMID: 34617588
- DOI: 10.1111/bjd.20712
Alopecia areata: progress, but who pays?
Comment on
-
The epidemiology of alopecia areata: a population-based cohort study in UK primary care.Br J Dermatol. 2022 Feb;186(2):257-265. doi: 10.1111/bjd.20628. Epub 2021 Oct 21. Br J Dermatol. 2022. PMID: 34227101 Free PMC article.
References
-
- King B, Guttman-Yassky E, Peeva E et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol 2021; 85:379-87.
-
- Xing L, Dai Z, Jabbari A et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 2014; 20:1043-9.
-
- Harries M, Macbeth AE, Holmes S et al. The epidemiology of alopecia areata: a population-based cohort study in UK primary care. Br J Dermatol 2022; 186:257-65.
-
- Lee HH, Gwillim E, Patel KR et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol 2020; 82:675-82.
-
- National Institute of Health and Care Excellence. Baricitinib for moderate to severe rheumatoid arthritis. Available at: https://www.nice.org.uk/guidance/ta466/documents/final-appraisal-determi... (last accessed 27 July 2021).
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
